

BioSketch – James M. Gallo

Education

University of Wisconsin, Madison, WI	1970-1973	College of Letters & Science
Mass. College of Pharmacy, Boston, MA	1973-1975	B.S., Pharmacy
University of Florida, Gainesville, FL	1977-1979	PharmD., Pharmacy
University of Arizona, Tucson, AZ	1979-1985	Ph.D., Pharmacy

POSITIONS

1985-1990	Assistant Professor of Pharmaceutics, University of Georgia
1990-1992	Associate Professor of Pharmaceutics, University of Georgia,
5/91-8/91	Visiting Scholar, Northwestern University Medical School Neuro-Oncology Program
2/93-6/96	Associate Member, Director, Pharmacokinetics Laboratory, Fox Chase Cancer Center
6/96-2003	Member, Dept. of Pharmacology, Director, Pharmacokinetics Lab, Fox Chase Cancer Center
6/03-8/04	Senior Member, Dept. of Pharmacology, Director, Pharmacokinetics Lab., Fox Chase Cancer Center
8/04-date	Professor, Schools of Medicine and Pharmacy, Temple University Director, Bioanalytical and Pharmacokinetic Center, Temple University

SELECTED PEER-REVIEWED PUBLICATIONS (*from over a 100*)

- Gallo, J.M.**, Swagler, A.R., Mehta, M., Qian, M. Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, VI: Effect of the calcium channel blocker nimodipine on zidovudine kinetics in monkeys. *J. Pharmacol. Exp. Ther.* **264**:315-320, 1993.
- Gallo, J.M.**, Hassan, E.E., Groothuis, D.G. Targeting anticancer drugs to the brain, II: Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. *J. Pharmacokin. Biopharm.* **21**:575-592, 1993.
- Gallo, J.M.**, Brennan, J., Halbherr, T., Laub, P., Ozols, R.F., O'Dwyer, P.J. Time-dependent pharmacodynamic models in cancer chemotherapy: Population pharmacodynamic model for glutathione depletion following administration of buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. *Cancer Res.* **55**:4507-4511, 1995.
- Devineni, D., Klein-Szanto, A., **Gallo, J.M.** *In vivo* microdialysis to characterize drug transport in brain tumors: Analysis of methotrexate uptake in rat glioma-2 (RG-2) bearing rats. *Cancer Chemother. Pharmacol.* **38**:499-507, 1996.
- Devineni, D., Klein-Szanto, A., **Gallo, J.M.** Uptake of temozolomide in a rat glioma model in the absence and presence of the angiogenesis inhibitor, TNP-470. *Cancer Res.* **56**:1983-1987, 1996.
- O'Dwyer, P.J., Laub, P.B., DeMaria, D., Qian, M., Reilly, D., Giantonio, B., Johnston, A.L., Wu, E.Y., Bauman, L., Clendenin, N.J., **Gallo, J.M.** Phase I trial of the thymidylate synthetase inhibitor AG-331 as a 5-day continuous infusion. *Clin. Cancer Res.* **2**:1685-1692, 1996.

- Obasaju, C.K., Johnson, S.W., Rogatko, A., Brennan, J.M., Kilpatrick, D., Hamilton, T.C., Ozols, R.F., O'Dwyer, P.J., **Gallo, J.M.** Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. *Clin. Cancer Res.* **2**:549-552, 1996.
- Qian, M., Chen, S.-H., von Hofe, E., **Gallo, J.M.** Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense oligonucleotide and its catabolites in tumor-bearing nude mice. *J. Pharmacol. Exp. Ther.* **282**:663-670, 1997.
- Ma, J., **Gallo, J.M.** Delivery of cytotoxic drugs from carrier cells to tumor cells by apoptosis. *Apoptosis* **3**:195-202, 1998.
- Ma, J., Zhou-Li, F., Klein-Szanto, A., **Gallo, J.M.** Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. *Clin. Exp. Metas.* **16**:559-568, 1998.
- Gallo, J.M.**, Laub, P.B., Rowinsky, E.K., Grochow, L.B., Baker, S.D. Population pharmacokinetic model for topotecan derived from phase I clinical trials. *J. Clin. Oncol.* **18**:2459-2467, 2000.
- Hudes, G.R., Szarka, C.E., Adams, A., Ranganathan, S., McCauley, R.A., Weiner, L.M., Langer, C.J., Litwin, S., Yeslow, G., Halber, T., Qian, M., **Gallo, J.M.** Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. *Clin. Cancer Res.* **6**:3071-3080, 2000.
- O'Dwyer, P.J., Szarka, C., Brennan, J.M., Laub, P.B., **Gallo, J.M.** Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects following a single oral dose. *Clin. Cancer Res.* **6**:4692-4696, 2000.
- Ma, J., Pulfer, S., Li, S., Chu, J., Reed, K., **Gallo, J.M.** Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. *Cancer Res.* **61**:5491-5498, 2001.
- Guo, P., Ma, J., Li, S., Guo, Z., Adams, A., **Gallo, J.M.** Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain-tumors in a xenograft model. *Cancer Chemother. Pharmacol.* **48**:169-176, 2001.
- Ma, J., Reed, K., **Gallo, J.M.** Cells designed to deliver anticancer drugs by apoptosis. *Cancer Res.* **62**:1382-1387, 2002.
- Ma, J., Murphy, M., O'Dwyer, P.J., Berman, E., Reed, K., **Gallo, J.M.** Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. *Biochem. Pharmacol.* **63**:1219-1228, 2002.
- Shen, M., Schilder, R.J., Obasaju, C., **Gallo, J.M.** Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. *Cancer Chemother. Pharmacol.* **50**:243-250, 2002.
- Guo, P., Li, S., **Gallo, J.M.** Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry. *J. Chromatogr. B* **783**:43-52, 2003.
- Ma, J., Li, S., Reed, K., Guo, P., **Gallo, J.M.** Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide (TMZ) in subcutaneous and intracerebral human glioma xenograft models. *J. Pharmacol. Exp. Ther.* **305**:833-839, 2003.
- Trapani, G., Lacquintana, V., Latrofa, A., Ma, J., Reed, K., Serra, M., Biggio, G., Liso, G., **Gallo, J.M.** Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors. *Bioconj. Chem.* **14**:830-839, 2003.
- Gallo, J.M.**, Li, S., Guo, P., Reed, K., Ma, J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. *Cancer Res.* **63**:5114-5117, 2003.

- Guo, P., Ma, J., Li, S., **Gallo, J.M.** Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography-mass spectrometry. *J. Chromatogr.* **798**:79-86, 2003.
- De Jongh, F.E., **Gallo, J.M.**, Shen, M., Verweij, J., Sparreboom, A. Population pharmacokinetics of cisplatin in adult cancer patients. *Cancer Chemother. Pharmacol.* **54**:105-112, 2004.
- Gallo, J.M.**, Vicini, P., Orlansky, A., Li, S., Zhou, F., Ma, J., Pulfer, S., Bookman, M.A., Guo, P. Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors. *Clin. Cancer Res.* **10**:8048-8058, 2004.
- Zhou, S. and **Gallo, J.M.** . In Vivo Microdialysis for Pharmacokinetic and Pharmacodynamic Studies of Anticancer Drugs. *AAPS Journal*, **7**:E659-E667, 2005.
- Mitsuuchi, Y., Powell, D. R., and **Gallo, J. M.** Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor. *Oncogene*, **25**:954-958, 2006.
- M.E. Cianfrocca, K.A. Kimmel, **J.M. Gallo**, T. Cardoso, M.M. Brown, G. Hudes, N. Lewis, L. Weiner, G.N. Lam, S.C. Brown, D.E. Shaw, A.P. Mazur, R.B. Cohen. Phase I trial of the antiangiogenic peptide ATN-161[Ac-PHSCN-NH₂], a beta integrin antagonist, in patients with solid tumors. *Br. J. Cancer*, **94**:1621-1626, 2006.
- P. Guo, X. Wang, L. Liu, and **J. M. Gallo**. Determination of methotrexate and its major metabolite 7-hydroxy methotrexate in mouse plasma and brain tissue by liquid chromatography - tandem mass spectrometry, *J. Pharmaceu. Biomed. Anal.*, **43**:1789-95. 2007.
- G.D. Kruh, M.G. Belinsky, **J.M. Gallo**, and K. Lee. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. *Cancer Metas Reviews*, **26**:5-14, 2007.
- Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchhaveleva I, Klein-Szanto A, **Gallo JM**, Kruh GD. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. *Cancer Res.*, **67**(1):262-8, 2007.
- Zhou Q, Guo P, Wang X, Nuthalapati S, **Gallo JM**. Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens. *J. Pharmacol. Exp. Ther.*, **321**:265-75, 2007.
- Q. Zhou, P. Guo, G. D. Kruh, P. Vicini, X. Wang, **J. M. Gallo**. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. *Clin. Cancer Res.*, **13**:4271-4279, 2007.
- S. Wang, P. Guo, X. Wang, Q. Zhou, **J.M. Gallo**. Preclinical pharmacokinetic-pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Accepted for Publication, *Mol. Cancer Therapeu.*
- Q. Zhou, P. Guo, and J. M. Gallo. Impact of antiangiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Accepted for Publication, *Clin. Cancer Res.*